Ameerika Ühendriigid - inglise - NLM (National Library of Medicine)

a-s medication solutions - hepatitis b virus subtype adw hbsag surface protein antigen (unii: xl4hlc6jh6) (hepatitis b virus subtype adw hbsag surface protein antigen - unii:xl4hlc6jh6) - hepatitis b virus subtype adw hbsag surface protein antigen 10 ug in 1 ml - recombivax hb® [hepatitis b vaccine, recombinant] is indicated for prevention of infection caused by all known subtypes of hepatitis b virus. recombivax hb is approved for use in individuals of all ages. recombivax hb dialysis formulation is approved for use in adult predialysis and dialysis patients 18 years of age and older. do not administer recombivax hb to individuals with a history of severe allergic or hypersensitivity reactions (e.g. , anaphylaxis) after a previous dose of any hepatitis b-containing vaccine or to any component of recombivax hb, including yeast [see description (11)] . risk summary all pregnancies have a risk of birth defect, loss, or other adverse outcomes. in the us general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4%, and 15% to 20%, respectively. there are no adequate and well-controlled studies designed to evaluate recombivax hb in pregnant women. available post-approval data do not suggest an in

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 720 eu/ml;  ; hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis a vaccine 720 eu/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - active: hepatitis a vaccine 720 eu/ml   hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids formaldehyde neomycin sulfate phenoxyethanol polysorbate 20 sodium chloride water for injection active: hepatitis a vaccine 720 eu/ml hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids dibasic sodium phosphate monohydrate formaldehyde monobasic sodium phosphate dihydrate neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - twinrix is indicated for active immunisation against hepatitis a and hepatitis b virus infection in adults. twinrix is also indicated for active immunisation against hepatitis a and hepatitis b virus infection in infants, children and adolescents from 1 year up to and including 15 years of age at risk of, or who wish to be protected against, both infections.

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 720 eu/ml;  ; hepatitis b surface antigen, recombinant 20 µg/ml; hepatitis a vaccine 720 eu/ml; hepatitis b surface antigen, recombinant 20 µg/ml - suspension for injection - active: hepatitis a vaccine 720 eu/ml   hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids formaldehyde neomycin sulfate phenoxyethanol polysorbate 20 sodium chloride water for injection active: hepatitis a vaccine 720 eu/ml hepatitis b surface antigen, recombinant 20 µg/ml excipient: aluminium amino acids dibasic sodium phosphate monohydrate formaldehyde monobasic sodium phosphate dihydrate neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - twinrix junior is indicated for active immunisation against hepatitis a and hepatitis b virus infection in infants, children and adolescents from 1 year up to and including 15 years of age at risk of, or who wish to be protected against, both infections.

Kanada - inglise - Health Canada

sanofi pasteur limited - salmonella typhi vi capsular polysaccharide vaccine; hepatitis a vaccine, inactivated - solution - 25mcg; 160unit - salmonella typhi vi capsular polysaccharide vaccine 25mcg; hepatitis a vaccine, inactivated 160unit - vaccines

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis a virus inactivated - suspension for injection

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis a virus inactivated - suspension for injection

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis a virus inactivated - suspension for injection

Suurbritannia - inglise - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - hepatitis a virus inactivated - suspension for injection

Uus-Meremaa - inglise - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - hepatitis a vaccine 1440 eu/ml (virus antigen (hm175 strain)); vi capsular polysaccharide of s. typhi ty2 25 µg/ml;   - suspension for injection - active: hepatitis a vaccine 1440 eu/ml (virus antigen (hm175 strain)) vi capsular polysaccharide of s. typhi ty2 25 µg/ml   excipient: aluminium hydroxide amino acids formaldehyde neomycin sulfate polysorbate 20 sodium chloride trometamol water for injection - hepatyrix is indicated for active immunisation of adults and adolescents older than 15 years of age at risk of both hepatitis a virus infection and typhoid fever. immunisation with hepatyrix is particularly recommended in subjects who are, or will be, at increased risk of infection such as travellers from countries of low endemicity to areas where the prevalence of hepatitis a and typhoid fever is high.

Iisrael - inglise - Ministry of Health

medici medical ltd, israel - hepatitis a vaccines - suspension for injection - hepatitis a vaccines 160 au / 0.5 ml - hepatitis a, inactivated, whole virus - hepatitis a, inactivated, whole virus - for active immunisation against infection caused by hepatitis a virus in adults and adolescents over the age of 15